Inherited renal cell carcinoma

British Journal of Urology

Volumn 78, Issue 4, 1996, Pages 542-545

  Maher, E R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLEAR CELL CARCINOMA; FAMILIAL CANCER; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHERITANCE; KIDNEY CARCINOMA; MOLECULAR GENETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; UROGENITAL TRACT TUMOR;

EID: 0030423208     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.01749.x     Document Type: Review

References (45)

1. Maher ER, Yates JRW. Familial renal cell carcinoma: clinical and molecular genetic aspects. Br J Cancer 1991; 63: 176-9
2. Maher ER, Yates JRW, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von HippelLindau disease and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 1990; 27: 311-4
3. Latif F, Tory K, Gnarra J et al. Isolation of the von HippelLindau disease tumour suppressor gene. Science 1993; 260: 1317-20
4. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Path Res Pract 1986; 181: 125-43
5. Kovacs G, Wilkens L, Papp T, De Riese W. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst 1989; 81: 527-30
6. Maher ER, Yates JRW, Harries R et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77: 1151-63
7. Maher ER. Von Hippel-Lindau disease. Eur J Cancer 1994; 30A: 1987-90
8. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 194: 629-42
9. Choyke PL, Glenn GM, Walther MM et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. Am J Res 1992; 159: 1229-34
10. Steinbach F, Novick AC, Zincke H et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 1995; 153: 1812-6
11. Walther MM, Choyke PL, Weiss G et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 1995; 153: 913-6
12. Richards FM, Crossey PA, Phipps ME et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 1994; 3: 595-8
13. 3 Crossey PA, Richards FM, Foster K et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994; 3: 1303-8
14. Chen F, Kishida T, Yao M et al. Germ line mutations in the von Hippel Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5: 66-75
15. Zbar B. Kishida T. Chen F. Germline mutations in the von Hippel-Lindau disease. VHL gene in families from North America, Europe and Japan. Hum Mutat 1996: in press
16. Brauch H, Kishida T, Glavac D et al. von Hippel Lindau disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995; 95: 551-6
17. Maher ER. Webster AR. Richards FM et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996: 33: 328-32
18. Duan DR. Pause A. Burgess WH et al Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995; 269: 1402-6
19. Aso T. Lane WS. Conaway JW. Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995; 269: 1439-43
20. Kibel A, Iliopoulos 0. DeCaprio JA, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995: 269: 1444-6
21. Tory K, Brauch H, Linehan M et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer lust 1989: 81: 1097-101
22. Crossey PA. Foster K, Richards FM et al. Molecular genetic investigation of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994: 93: 53-8
23. Foster K, Prowse A. van den Berg A et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169-73
24. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet 1994; 54: 2852-5
25. Shuin T. Kondo K, Torigoe S et al. Frequent somatic mutations and loss of heterozygosity of the von HippelLindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1996: in press
26. Herman JG. Latif F. Weng Y et al. Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinomas. Proc Natl Acad Sei USA 1994; 91: 9700-4
27. Iliopoulos 0. Kibel A, Gray S. Kaelin WG Tumour suppression by the human von Hippel-Lindau gene product. Nature Med 1995: 1: 822-6
28. Crossey PA. Eng C, Ginalska-Malinowska M et al. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet 1995; 32: 885-6
29. Neumann HPH, Eng C, Mulligan L et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type 2. JAMA 1995; 274: 1149-51
30. Cohen AJ, Li FF. Berg S et al. Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979; 301: 592-5
31. Kovacs G, Brusa P,De Riese W. Tissue-specific expression of a constitutional 3:6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989: 43: 422-7
32. Schmidt L, Li F. Bron RS et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional 3:8 translocation. Cancer J Sei Am 1995: 1: 191-5
33. Ohta M, Inoue H, Cotticelli MG et al. The FHIT gene, spanning the chromosome 3pl4. 2 fragile site and renal carcinoma-associated t(3: 8) breakpoint, is abnormal in digestive tract cancers. Cell 1996: 84: 587-97
34. Zbar B, Glenn G. Lubensky I et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995: 153: 907-12
35. Zbar B. Tory K. Merino M et al. Hereditary papillary renal cell carcinoma. J Urol 1994: 151: 561-6
36. Van den Berg E. Van der Hout AH, Oosterhuis J et al. Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classiiication. Int J Cancer 1993: 55: 223-7
37. Thrash-Bingham CA, Salazar H. Freed JJ. Grrenberg RE. Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995: 55: 6189-95
38. Suijkerbuijk RF, Meloni AM. Sinke RJ et al. Identification of a yeast artificial chromosome that spans the human papillary renal cell carcinoma-associated t(X;l) breakpoint in Xpll. 2. Cancer Genet Cijtogenet 1993: 71: 164-9
39. Yeung RS. Xiao GH. Jin F. Lee WC, Testa Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Mat Acad Sei 1994: 91: 1141 3-6
40. Kobayashi T. Hirayama Y. Kobayashi E, Kubo Y. Hino 0. A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nature Genet 1995: 9: 70-4
41. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993: 75: 1305-15
42. Sampson Harris PC. The molecular genetics of tuberous sclerosis. Hum Mol Genet 1994: 3: 1477-80
43. Brook-Carter PT, Peral B. Ward CJ et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease -a contiguous gene syndrome. Mature Genet 1994; 8: 328-32
44. Green AJ. Smith M. Yates Loss of heterozygosity on chromosome 16pl3. 3 in hamartomas from tuberous sclerosis patients. Nature Genet 1994; 6: 193-6
45. Aaltonen LA. Peltomaki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 810-2